Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check7 days agoChange DetectedThis change adds new revision history entries (2026-07-23, 2026-07-22) and a Revision: v3.6.4, and removes the previous revision entry (v3.6.3). The updates reflect site maintenance/versioning metadata for the page rather than changes to the study content.SummaryDifference0.2%

- Check15 days agoChange DetectedNew update dates were added for 2026-07-15 through 2026-07-17, and older update dates were removed (2026-02-20, 2026-07-07, 2026-07-08). This reflects maintenance of the page's update history rather than changes to the study data.SummaryDifference0.2%

- Check22 days agoChange DetectedThe study record's update history shows new timestamps for 2026-07-08 and 2026-07-07, and older entries were removed; this reflects maintenance of the log rather than changes to the study details.SummaryDifference0.2%

- Check29 days agoChange DetectedA new revision entry (v3.6.3) dated 2026-07-02 was added, and the prior revision (v3.6.2) from June 2026 was removed. This reflects routine maintenance of the study record’s version history rather than substantive changes to the study details.SummaryDifference0.2%

- Check36 days agoChange DetectedThe page revision has been updated from v3.6.0 to v3.6.2, reflecting an internal update to the page. This change does not affect the study details, eligibility criteria, or user-facing features.SummaryDifference0.0%

- Check51 days agoChange DetectedNew navigation links were added to help users find who can join, contact information, how to read a study record, common questions, and how to join, and a version stamp 'Revision: v3.6.0' was introduced. The existing 'Intervention / Treatment' label was updated to 'Intervention/Treatment' to standardize terminology.SummaryDifference0.5%

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.